Treatment of breast cancer stem cells with oncolytic herpes simplex virus

Cancer Gene Therapy

Volumn 19, Issue 10, 2012, Pages 707-714

  Li, J ^a,b   Zeng, W ^a   Huang, Y ^a   Zhang, Q ^a   Hu, P ^a   Rabkin, S D ^c   Liu, R ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SICHUAN CANCER HOSPITAL   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

breast cancer; cancer stem cells; HSV; oncolytic virus

Indexed keywords

BETA GALACTOSIDASE; CD24 ANTIGEN; HERMES ANTIGEN; ONCOLYTIC HERPES VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER STEM CELL; CARCINOGENESIS; CELL CULTURE; CELL GROWTH; CELL SUSPENSION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VIRUS REPLICATION;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY; SIMPLEXVIRUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; SIMPLEXVIRUS;

EID: 84866383076     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.49     Document Type: Article

References (35)

1. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009; 59: 27-41.
2. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
3. Lawson JC, Blatch GL, Edkins AL. Cancer stem cells in breast cancer and metastasis. Breast Cancer Res Treat 2009; 118: 241-254.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
5. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009; 15: 4234-4241.
6. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
7. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-783.
8. Eriksson M, Guse K, Bauerschmitz G, Virkkunen P, Tarkkanen M, Tanner M et al. Oncolytic adenoviruses kill breast cancer initiating CD44 +CD24-/low cells. Mol Ther 2007; 15: 2088-2093.
9. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66: 11954-11966.
10. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006; 24: 506-511.
11. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci 2007; 28: 326-333.
12. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9: 967-978.
13. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867-874.
14. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17: 199-207.
15. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
16. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98: 6396-6401.
17. Liu R, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther 2005; 12: 647-654.
18. Liu RB, Rabkin SD. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer. Chin Med J (Engl) 2005; 118: 307-312.
19. Liu R, Varghese S, Rabkin SD. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res 2005; 65: 1532-1540.
20. Huang MZ, Zhang FC, Zhang YY. Influence factors on the formation of mammospheres from breast cancer stem cells. J Peking Univ (Health Science) 2008; 40: 500-504.
21. Alvi AJ, Clayton H, Joshi C, Enver T, Ashworth A, Vivanco MM et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res 2003; 5: R1-R8.
22. Li T, Yang Y, Hua X, Wang G, Liu W, Jia C, Tai Y et al. Hepatocellular carcinomaassociated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett 2012; 318: 154-161.
23. Huang CY, Pelaez D, Dominguez-Bendala J, Garcia-Godoy F, Cheung HS. Plasticity of stem cells derived from adult periodontal ligament. Regen Med 2009; 4: 809-821.
24. Akira O, Piyush BG, Dennis CS, Fernando AS, Thierry D, Rizwan N et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
25. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nature 2006; 6: 392-401.
26. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65: 5506-5511.
27. Li HZ, Yi TB, Wu ZY. Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells. BMC Cancer 2008; 8: 135.
28. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44 + breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777-1785.
29. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120: 41-50.
30. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2 + and ABCG2-cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-6219.
31. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217-226.
32. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-1123.
33. Aghi M, Martuza RL. Oncolytic viral therapies-the clinical experience. Oncogene 2005; 24: 7802-7816.
34. Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T, Goshima F et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol 2006; 13: 1078-1084.
35. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-6747.